# DDI Study of Evobrutinib and Carbamazepine

> **NCT05248945** · PHASE1 · COMPLETED · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 14 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Evobrutinib
- **DRUG:** Carbamazepine

## Key facts

- **NCT ID:** NCT05248945
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-13
- **Primary completion:** 2022-07-18
- **Final completion:** 2022-07-18
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05248945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05248945, "DDI Study of Evobrutinib and Carbamazepine". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05248945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*